Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 25;7(2):204-211.
doi: 10.1093/jcag/gwad049. eCollection 2024 Apr.

Perceptions and Prevalence of Cannabis Use in Women With Inflammatory Bowel Disease of Reproductive Age: A Cross-Sectional Study

Nariman Hossein-Javaheri  1 , Katie O'Connor  2 , Hillary Steinhart  2 , Amol Deshpande  3 , Cynthia Maxwell  4 , Vivian Huang  2 , Parul Tandon  2
Affiliations

Perceptions and Prevalence of Cannabis Use in Women With Inflammatory Bowel Disease of Reproductive Age: A Cross-Sectional Study

Nariman Hossein-Javaheri et al. J Can Assoc Gastroenterol. .

Abstract

Background: Many patients with inflammatory bowel disease (IBD) may use cannabis for relief of symptoms. During pregnancy, however, cannabis exposure may be associated with adverse pregnancy outcomes. We aimed to determine the prevalence and perceptions of cannabis use in women with IBD.

Methods: Through recruitment at Mount Sinai Hospital and online platforms such as Twitter, women with IBD (age 18-45) were asked to complete anonymous surveys on demographics, cannabis use, perception of use during pregnancy, and discussing its use with healthcare providers (HCP). Categorical variables were reported as frequencies and compared across groups with the chi-square test.

Results: One-hundred and two pregnant patients with IBD were included in this study, 19 (18.6%) reported using cannabis. Current users were more likely to report constant pain in the last 12 months and discuss its use with their HCP. Fifty-three (52.0%) women were unsure of the specific risks associated with cannabis use during pregnancy, and only 15 (14.7%) had ever discussed its use with their HCP. Those who had discussed cannabis use with their HCP were more likely to have prior IBD-related surgery, perceive its use unsafe during pregnancy, and be more likely to be using cannabis.

Conclusion: Many women with IBD report uncertainty of the risks of cannabis use during pregnancy and the majority have never discussed cannabis use with their providers. With the increasing legalization of cannabis in many jurisdictions, it is imperative patients and healthcare providers discuss the risks and benefits of its use, particularly during vulnerable times such as pregnancy.

Keywords: Crohn’s disease; IBD; cannabis; pregnancy; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Dr. Steinhart has received education grants from Abbvie, Celgene (BMS), Janssen, Arena (Pfizer), Genentech/Roche, and Takeda; Has served as a consultant for Abbvie, BioJAMP, Fresenius Kabi, McKesson, Organon, Pfizer, Takeda, Lilly, Amgen, BMS, Janssen, Mylan Pharmaceuticals, Pendopharm, Sandoz, Viatris; Has attended educational events sponsored by Abvvie, BMS, Organon, Takeda, Amgen, Janssen, and Pfizer. Dr. Tandon has attended educational events supported by Takeda and Janssen. Other authors have no conflict of interest to report.

Figures

Figure 1.
Figure 1.
(A) Percentage of cannabis users at the time of the survey. (B) Percentage of patients who were aware of the risks of cannabis during pregnancy. (C) Percentage of patients who had discussed cannabis use with their health-care providers (HCP).
See this image and copyright information in PMC

References

    1. Kaplan, Gilaad G, Bernstein Charles N, Coward Stephanie, Bitton Alain, Murthy Sanjay K, Nguyen Geoffrey C, Lee Kate, Cooke-Lauder Jane, and Benchimol. Eric I. “The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology.” J Can Assoc Gastroenterol 2, no. Suppl 1 (2019): S6–S16. 10.1093/jcag/gwy054. https://www.ncbi.nlm.nih.gov/pubmed/31294381 - DOI - PMC - PubMed
    1. Zeitz, Jonas, Ak Melike, Müller-Mottet Séverine, Scharl Sylvie, Biedermann Luc, Fournier Nicolas, Frei Pascal,. et al.; Swiss IBD Cohort Study Group. ““Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account.” [In Eng] PLoS One 11, no. 6 (2016): e0156666. 10.1371/journal.pone.0156666 - DOI - PMC - PubMed
    1. Storr, Martin, Devlin Shane, Kaplan Gilaad G, Panaccione Remo, and Andrews. Christopher N. “Cannabis Use Provides Symptom Relief in Patients with Inflammatory Bowel Disease but Is Associated with Worse Disease Prognosis in Patients with Crohn’s Disease.” [In Eng] Inflammatory Bowel Diseases 20, no. 3 (2014): 472–80. 10.1097/01.MIB.0000440982.79036.d6 - DOI - PubMed
    1. Naftali, Timna, Bar-Lev Schleider Lihi, Sklerovsky Benjaminov Fabiana, Lish Ido, Konikoff Fred M, and Ringel. Yehuda. “Medical Cannabis for Inflammatory Bowel Disease: Real-Life Experience of Mode of Consumption and Assessment of Side-Effects.” European Journal of Gastroenterology and Hepatology 31, no. 11 (2019): 1376–81. 10.1097/MEG.0000000000001565. https://www.ncbi.nlm.nih.gov/pubmed/31567639 - DOI - PubMed
    1. Lafaye, Genevieve, Karila Laurent, Blecha Lisa, and Benyamina. Amine. “Cannabis, Cannabinoids, and Health.” Dialogues in Clinical Neuroscience 19, no. 3 (2017): 309–16. 10.31887/dcns.2017.19.3/glafaye. https://www.ncbi.nlm.nih.gov/pubmed/29302228 - DOI - PMC - PubMed

LinkOut - more resources